Suzhou Eyre cleared for penicillin production by SFDA

- Last updated on GMT

Related tags: Penicillin

Suzhou Erye Pharmaceutical has received SFDA approval to make penicillin at its new manufacturing facility in Eastern China.

The firm, a subsidiary of US stem cell specialist NeoStem, has got the OK to make both solvent crystallised and freeze dried raw sterile penicillin at the plant, which generates 20 per cent of its income each year.

NeoStem CEO Robin Smith said that gaining Chinese Food and Drug Administration (SFDA) approval is part of a wider project to transfer manufacturing operations to the new facility over the next 12 months.

Once Erye has completed its relocation to the new facility, and its new production lines are fully operational, it will have substantially increased its capacity from the current plant with the goal of becoming among the largest antibiotic producers in Eastern China​."

Related news

Related products

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us

Products

View more

Webinars